ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
46 announcements
Astec LifeSciences Limited confirmed the full utilization of ₹49 Crore raised through Private Placement of Non-Convertible Debentures. The company reported no deviations or variations in the use of proceeds for the quarter ended March 31, 2026.
Astec LifeSciences reported a 17.1% year-on-year increase in FY26 consolidated total income to ₹453.2 Crore. Despite a loss after tax of ₹80.9 Crore, the company achieved EBITDA breakeven at ₹0.5 Crore. Growth was primarily driven by improved volumes in the Enterprise and CDMO segments.
Astec Lifesciences Ltd reported revenue from operations of ₹158.6 Cr (+32.7% YoY) and a net loss of ₹7.5 Cr for Q4 FY26.
Astec LifeSciences Limited reported its audited financial results for the quarter and year ended March 31, 2026. The Board also approved the appointment of new directors including Mr. Vishal Sharma and Mr. Burjis Godrej as Non-Executive Directors, and fixed July 31, 2026, as the date for its 32nd Annual General Meeting.
Astec LifeSciences Limited submitted its annual disclosure for the centralized database of corporate bonds as of March 31, 2026. The filing confirms listing details and interest payment status for its ₹49 Crore Non-Convertible Debentures (ISIN: INE563J08023). ICRA reaffirmed the credit rating at [ICRA]AA- with a negative outlook.
Astec LifeSciences Limited clarified to NSE that there are no undisclosed price-sensitive developments or events requiring disclosure under SEBI regulations. The company confirmed compliance with all listing and insider trading regulations, stating that recent share price movements are market-driven and not linked to any internal corporate actions.
Astec LifeSciences Ltd clarified to BSE that there are no undisclosed price-sensitive developments or events requiring disclosure under SEBI regulations. The company confirmed compliance with all listing and insider trading regulations. This response follows a clarification sought by the exchange regarding recent share price movement.
Astec LifeSciences Limited has scheduled a Board Meeting for Monday, April 27, 2026. The board will consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
Astec LifeSciences Limited has scheduled a Board Meeting for April 27, 2026. The Board will consider and approve the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
Astec LifeSciences Limited successfully redeemed its Commercial Paper (Series Astec-CP-188) by making a timely payment of ₹25 Crore on April 15, 2026. The instrument, originally issued in November 2025, was listed on the NSE.
Astec LifeSciences Limited announced a major management shuffle effective April 13, 2026. Nadir Godrej will retire, while Vishal Sharma is appointed as CEO (Chemicals). Burjis Godrej transitions to a Non-Executive Director role. Additionally, Mathew Eipe joins as an Independent Director and Arijit Mukherjee is appointed to the Board, strengthening leadership across the Godrej Industries Group.
Astec LifeSciences announced major leadership changes: Mr. Nadir Godrej retired as Chairman, succeeded by Mr. Vishal Sharma. Mr. Burjis N. Godrej stepped down as Managing Director to become a Non-Executive Director, while Mr. Arijit Mukherjee was appointed Executive Director and COO. These strategic board transitions are effective from April 13, 2026.
Astec LifeSciences announced major leadership changes: Mr. Nadir Godrej retired as Chairperson, replaced by Mr. Vishal Sharma. Mr. Burjis Godrej resigned as Managing Director to move to the parent company, remaining as a Non-Executive Director. Additionally, Mr. Mathew Eipe and Mr. Arijit Mukherjee were appointed to the Board, with the latter as COO for a three-year term.
Astec LifeSciences Limited certified that it did not issue any fresh Commercial Paper (CP) during the quarter ended March 31, 2026. This filing is a regulatory compliance confirmation regarding the utilization and status of issue proceeds under SEBI regulations.
Astec LifeSciences Limited reported the status of its private placement debt securities for the half-year ended March 31, 2026. The company has ₹49 Crore outstanding in 8.90% Non-Convertible Debentures (ISIN: INE563J08023) maturing in March 2027. This filing is a routine regulatory disclosure under SEBI's master circular for debt securities.
Astec Lifesciences Ltd reported a net loss of ₹15.7 Cr for Q3 FY26.